Cartography Bio Corrals $67M to Bring Targeted Colorectal Cancer Drug Into the Clinic

Cartography Bio Corrals $67M to Bring Targeted Colorectal Cancer Drug Into the Clinic

Pfizer Ventures led the Series B financing of Cartography Biosciences, whose lead program addresses a promising target for colorectal cancer. The startup’s drugs come from platform technologies that analyze data from healthy cells and cancer cells to identify cancer-specific targets. The post Cartography Bio Corrals $67M to Bring Targeted Colorectal Cancer Drug Into the Clinic appeared first on MedCity News.

Cartography secures $67M in pursuit of ‘differentiated’ cancer drugs

The company is working on T cell engagers and other multifunctional antibodies, led by a prospect it believes might be helpful treating the vast majority of colorectal cancer cases.

Cartography Biosciences Raises $67M to Advance Next-Generation Colorectal Cancer Drug

Cartography Biosciences, a San Francisco Bay Area biotech, announced a $67 million Series B round to advance its lead drug candidate, CBI-1214, into clinical trials. CBI-1214 is a T cell engager designed to treat the most common form of colorectal cancer by drawing immune cells to tumors, potentially improving outcomes for patients with limited treatment options. The approach builds on recent successes of multi-target antibody drugs in blood can…

Cartography secures $67M in pursuit of ‘differentiated’ cancer drugs – RamaOnHealthcare

The San Francisco Bay Area biotech will use the funds to bring a T cell engager for colorectal cancer into the clinic.Dive Brief:Cartography Biosciences, a San Francisco Bay Area biotechnology company, announced Thursday it raised a $67 million Series B round to propel its first drug prospect into clinical testing.Its lead program, dubbed CBI-1214, is [...]